van der Kooij, Monique K. http://orcid.org/0000-0002-9764-5467
Joosse, Arjen
Suijkerbuijk, Karijn P. M.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
Blank, Christian U. http://orcid.org/0000-0002-7945-5846
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.
de Groot, Jan Willem B.
Haanen, John B. A. G.
Hospers, Geke A. P. http://orcid.org/0000-0002-3047-7892
Piersma, Djura
van Rijn, Rozemarijn S.
van der Veldt, Astrid A. M. http://orcid.org/0000-0003-0446-1907
Vreugdenhil, Gerard
Westgeest, Hans M. http://orcid.org/0000-0002-5735-3638
Wouters, Michel W. J. M.
Dekkers, Olaf M.
Kapiteijn, Ellen
Article History
Received: 4 April 2022
Revised: 4 November 2022
Accepted: 22 November 2022
First Online: 23 December 2022
Competing interests
: MJBS has served as an advisory board member for Bristol-Myers Squibb, Novartis, Merck and Pierre Fabre. AJMvdE has served as a speaker for Bristol-Myers Squibb and Novartis and an advisory board member for Bristol Myers Squibb, MSD oncology, Amgen, Roche, Novartis, Sanofi, Pfizer, Ipsen, Merck, Pierre Fabre and has received research grants not related to this paper from Sanofi, Roche, Bristol Myers Squibb, TEVA and Idera. CUB has served as ab advisory board member for Bristol-Myers Squibb, MSD, Roche, Novartis, GlaxoSmithKline, AstraZeneca, Pfizer, Lilly, GenMab, and Pierre Fabre, and reports to have ownership interests in Uniti Cars, Neon Therapeutics, and Forty Seven, and received commercial grants from Novartis, Bristol-Myers Squibb, and NanoString. JWBdG is a paid consultant for Bristol Myers Squibb, MSD, Pierre Fabre, and Servier. GAPH is an unpaid consultant/advisory board member for Bristol Myers Squibb, MSD, Roche, and Novartis. DP has served as an advisory board member for Amgen, Bristol Myers Squibb and Pierre Fabre. AAMvdV is a paid consultant for Bristol Myers Squibb, MSD, Novartis, Roche, Pfizer, Eisai, Ipsen, Pierre Fabre, Sanofi, and Bayer. JH is a paid consultant for AIMM, Neon Therapeutics, Immunocore, Vaximm, and Neogene Therapeutics, and reports receiving commercial research grants from Bristol Myers Squibb, MSD, Novartis, and Neon Therapeutics. KPMS has served as a consultant and/or advisory board member for Bristol Myers Squibb, Novartis, MSD, Pierre Fabre and AbbVie and received honoraria/research support not related to this manuscript from Novartis, Roche and MSD. All paid to institution. EK has served as a consultant and/or advisory board member for Bristol Myers Squibb, Novartis, Merck, Pierre Fabre and has received research grants not related to this paper from Bristol Myers Squibb. HMW received travel expenses from Ipsen and honoraria from Astellas and Roche. No potential conflicts of interest were disclosed by the other authors. Role of the funder: the funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
: The DMTR was approved by a medical ethical committee (METC Leiden University Medical Center, 2013) and is not considered subject to the Medical Research Involving Human Subjects Act. Patient consent was waived due to the fact that the DMTR was not considered to be subject to the Medical Research Involving Human Subjects Act.